MapLight Therapeutics, Inc. - 8-K Filing
MapLight Therapeutics reports Q3 2026 net loss of $51.6 million and announces $463.4 million cash position expected to fund operations through 2028. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $MPLT